SNY
Sanofi
NASDAQ · Healthcare · Drug Manufacturers - General · FR
$44.24
−0.20%Jun 23, 2026, 05:55 UTC
The European Commission approved Sanofi's Cenrifki for treating non-relapsing secondary progressive multiple sclerosis in adults.
Source:Jun 4, 2026, 09:55 UTC
Sanofi launched its 2026 global employee stock purchase plan, Action 2026, offering shares at a 20% discount to approximately 75,000 employees across 52 countries.
Source:
← PreviousPage 2